Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1135560

registered interest
date	28/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Autism and Learning Disability: Newcastle-under-Lyme
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made an estimate of the number of people in the Newcastle-under-Lyme constituency with (a) learning disabilities and (b) autism who have been in an Assessment and Treatment Unit for three months or longer; and if he will make a statement.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	270728
answer	answer is ministerial correction date of answer 03/07/2019 answer text <p>The information is not available in the format requested.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 03/07/2019 16:04:10 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1436 label Biography information for Paul Farrelly

1135182

registered interest
date	27/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genomics: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, which diagnostic tests will whole genome sequencing replace, particularly for blood cancers.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	270281
answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>During 2019, the National Health Service will begin to offer whole genome sequencing (WGS) as part of clinical care for:</p><p>- Seriously ill children likely to have a rare genetic disorder;</p><p>- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and acute myeloid leukaemia.</p><p> </p><p>WGS will only replace existing diagnostic tests once the testing is demonstrated to be clinically safe to replace existing diagnostic testing. Initially, existing diagnostic testing will continue to be performed alongside WGS testing where clinically appropriate. This will continue until WGS is able to fully support clinical decision making within clinically appropriate timescales.</p><p>Current testing for blood cancers includes a number of diagnostic tests, the current expectation is that WGS will not be used to replace tests that require very fast turnaround times (under 24 hours) or high sensitivity.</p><p>WGS and non-WGS testing that will be available as part of clinical care is outlined in the National Genomic Test Directory at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/national-genomic-test-directories/" target="_blank">https://www.england.nhs.uk/publication/national-genomic-test-directories/</a></p><p> </p><p>The UK Genetic Testing Network (UKGTN) published the NHS Directory of Genetic Disorders/Genes for Diagnostic Testing, which evaluated and recommended genetic tests for rare and inherited disorders for the National Health Service across the UK. However, there was not an equivalent for cancer genomic testing. The National Genomic Test Directory specifies which genomic tests are commissioned by the NHS in England, the technology by which they are available, and the patients who will be eligible to access to a test.</p><p>The National Genomic Test Directory will be updated on an annual basis and NHS England will implement a clear and transparent process, supported by a Clinical and Scientific Expert Panel, to determine which tests are available within the NHS. This will include reviewing any tests that may be retired or replaced by more modern technology, such as WGS. As the price of WGS falls and the clinical evidence improves, we envisage that it will be extended to more conditions and therefore more patients.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 270282 270283 question first answered 05/07/2019 09:24:02 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	394 label Biography information for Mr Clive Betts

1135183

registered interest
date	27/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genetics: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the National Genomic Test Directory directly replaces the NHS Directory of Genetic Disorders/Genes for Diagnostic Testing.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	270282
answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>During 2019, the National Health Service will begin to offer whole genome sequencing (WGS) as part of clinical care for:</p><p>- Seriously ill children likely to have a rare genetic disorder;</p><p>- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and acute myeloid leukaemia.</p><p> </p><p>WGS will only replace existing diagnostic tests once the testing is demonstrated to be clinically safe to replace existing diagnostic testing. Initially, existing diagnostic testing will continue to be performed alongside WGS testing where clinically appropriate. This will continue until WGS is able to fully support clinical decision making within clinically appropriate timescales.</p><p>Current testing for blood cancers includes a number of diagnostic tests, the current expectation is that WGS will not be used to replace tests that require very fast turnaround times (under 24 hours) or high sensitivity.</p><p>WGS and non-WGS testing that will be available as part of clinical care is outlined in the National Genomic Test Directory at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/national-genomic-test-directories/" target="_blank">https://www.england.nhs.uk/publication/national-genomic-test-directories/</a></p><p> </p><p>The UK Genetic Testing Network (UKGTN) published the NHS Directory of Genetic Disorders/Genes for Diagnostic Testing, which evaluated and recommended genetic tests for rare and inherited disorders for the National Health Service across the UK. However, there was not an equivalent for cancer genomic testing. The National Genomic Test Directory specifies which genomic tests are commissioned by the NHS in England, the technology by which they are available, and the patients who will be eligible to access to a test.</p><p>The National Genomic Test Directory will be updated on an annual basis and NHS England will implement a clear and transparent process, supported by a Clinical and Scientific Expert Panel, to determine which tests are available within the NHS. This will include reviewing any tests that may be retired or replaced by more modern technology, such as WGS. As the price of WGS falls and the clinical evidence improves, we envisage that it will be extended to more conditions and therefore more patients.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 270281 270283 question first answered 05/07/2019 09:24:02 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	394 label Biography information for Mr Clive Betts

1135184

registered interest
date	27/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genomics: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how will new tests be added to the National Genomic Test Directory.
tabling member constituency	Sheffield South East
tabling member printed	Mr Clive Betts
uin	270283
answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>During 2019, the National Health Service will begin to offer whole genome sequencing (WGS) as part of clinical care for:</p><p>- Seriously ill children likely to have a rare genetic disorder;</p><p>- People with one of 21 rare conditions where current evidence supports early adoption of WGS as a diagnostic test; and</p><p>- People with specific types of cancer for which there is likely to be the greatest patient benefit from using WGS – children with cancer, sarcoma and acute myeloid leukaemia.</p><p> </p><p>WGS will only replace existing diagnostic tests once the testing is demonstrated to be clinically safe to replace existing diagnostic testing. Initially, existing diagnostic testing will continue to be performed alongside WGS testing where clinically appropriate. This will continue until WGS is able to fully support clinical decision making within clinically appropriate timescales.</p><p>Current testing for blood cancers includes a number of diagnostic tests, the current expectation is that WGS will not be used to replace tests that require very fast turnaround times (under 24 hours) or high sensitivity.</p><p>WGS and non-WGS testing that will be available as part of clinical care is outlined in the National Genomic Test Directory at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/national-genomic-test-directories/" target="_blank">https://www.england.nhs.uk/publication/national-genomic-test-directories/</a></p><p> </p><p>The UK Genetic Testing Network (UKGTN) published the NHS Directory of Genetic Disorders/Genes for Diagnostic Testing, which evaluated and recommended genetic tests for rare and inherited disorders for the National Health Service across the UK. However, there was not an equivalent for cancer genomic testing. The National Genomic Test Directory specifies which genomic tests are commissioned by the NHS in England, the technology by which they are available, and the patients who will be eligible to access to a test.</p><p>The National Genomic Test Directory will be updated on an annual basis and NHS England will implement a clear and transparent process, supported by a Clinical and Scientific Expert Panel, to determine which tests are available within the NHS. This will include reviewing any tests that may be retired or replaced by more modern technology, such as WGS. As the price of WGS falls and the clinical evidence improves, we envisage that it will be extended to more conditions and therefore more patients.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 270281 270282 question first answered 05/07/2019 09:24:02 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	394 label Biography information for Mr Clive Betts

1135293

registered interest
date	27/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Legal Costs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 June 2019 to Question 266123 on NHS: Legal Costs, how his Department differentiates between individual projects or cases; and what steps his Department takes to (a) ensure that public funds paid to those legal services providers is in respect of work actually done or carried out by those providers and (b) record the areas of law and jurisdictions of courts and tribunals in which the work is done.
tabling member constituency	North Norfolk
tabling member printed	Norman Lamb
uin	270315
answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>The Department uses two main routes to engaging legal support.</p><p>- The Department’s Anti-Fraud Unit (AFU) engages external law firms through the Civil Litigation and Arbitration in Medicines and Pharmaceuticals Framework, as well as the Government Legal Department (GLD). The AFU utilises a case management system in order to differentiate between individual cases and checks are conducted against invoices and supporting documents submitted by each law firm, including GLD, to ensure these are reflective of their instructions.</p><p> </p><p>- Other business areas within the Department consult with the GLD on the resources available and should they not have the capacity then they will a conduct a competition for other Legal service providers using the Crown Commercial Services framework contract. GLD will ensure that deliverables are agreed and undertaken to the agreed quality before payments are made.</p><p> </p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 02/07/2019 16:11:28 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	1439 label Biography information for Norman Lamb

1135307

registered interest
date	27/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Care Homes: Closures
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of residential care homes that have closed in each year since 2010.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	270257
answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>The Department does not hold data on the number of care home and home care provider closures since 2010.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 270258 question first answered 02/07/2019 16:05:13 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	308 label Biography information for Mr Jim Cunningham

1135308

registered interest
date	27/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Home Care Services: Closures
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what estimate his Department has made of the number of home care providers that have closed since 2010.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	270258
answer	answer is ministerial correction date of answer 02/07/2019 answer text <p>The Department does not hold data on the number of care home and home care provider closures since 2010.</p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 270257 question first answered 02/07/2019 16:05:13 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	308 label Biography information for Mr Jim Cunningham

1134829

registered interest
date	26/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Antimicrobials: Drug Resistance
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what research his Department has undertaken (a) directly, (b) through research councils and (c) with international partners on antimicrobial resistance.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	269618
answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>The Department is investing over £1 billion a year in health research through the National Institute for Health Research (NIHR). The NIHR supports a wide portfolio of research on antimicrobial resistance (AMR) through various funding streams. In the United Kingdom, investment includes £32 million of capital funding to support AMR research, £19.1 million for AMR research at four NIHR Biomedical Research Centres, and £8.8 million for two NIHR Health Protection Research Units on Healthcare Associated Infections and Antimicrobial Resistance.</p><p>The NIHR also supports research into AMR in low and middle-income countries (LMICs), with official development assistance (ODA) funding through the NIHR Global Health Research programme. Investment includes support for the NIHR Global Health Research Unit on Genomic Surveillance of Antimicrobial Resistance, and the NIHR Global Health Research Group on Genomic Surveillance of Malaria in West Africa.</p><p>Working through partnerships with other UK funders, the NIHR Global Health Research programme also supports cross-Research Council initiatives including one led by the Medical Research Council for research into AMR in a global context, and another led by the Economic and Social Research Council to expand understanding of how behaviour within and beyond the healthcare system impacts on AMR.</p><p>In addition, the Department has allocated over £50 million of ODA over five years to AMR research through the Global AMR Innovation Fund. This research is delivered through a range of mechanisms and delivery partners, including research councils such as the Biotechnology and Biological Sciences Research Council and Innovate UK, and international partners including the Wellcome Trust, Bill and Melinda Gates Foundation, the United States and German governments, and Canada’s International Development Research Centre.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 05/07/2019 11:34:34 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	252 label Biography information for Dr David Drew

1134875

registered interest
date	26/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genomics: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, who will hold responsibility for adding new tests to the National Genomic Test Directory.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	269720
answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>The National Genomic Test Directory outlines which genomic tests are commissioned by the National Health Service in England, the technology by which they are available, and the patients who will be eligible to access to a test. The Directory will be updated on an annual basis and NHS England will implement a clear and transparent process, supported by a Clinical and Scientific Expert Panel, to determine which tests are available within the NHS. This will include reviewing any tests that may be retired or replaced by more modern technology, such as whole genome sequencing. As the price of whole genome sequencing falls and the clinical evidence improves, we envisage that it will be extended to more conditions and therefore more patients. More information on the Directory is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/national-genomic-test-directories/" target="_blank">https://www.england.nhs.uk/publication/national-genomic-test-directories/</a></p><p> </p><p>There is considerable variation in the reported costs of genomic analysis. For Genomics England, during the 100,000 Genomes project, these were in order of £2,500 per cancer patient. This included sequencing both the patient’s normal genome and their tumour, as well as the running costs of undertaking both the sequencing and bioinformatics for analysis and interpretation.</p><p>Health Education England established the Genomics Education Programme to support NHS staff to build the knowledge, skills and experience to deliver a whole genome sequencing service. This programme is being embedded into organisations to enable long-term sustainability of the multi-disciplinary clinical workforce.</p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 269721 269722 question first answered 05/07/2019 09:26:34 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4056 label Biography information for Nic Dakin

1134876

registered interest
date	26/06/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the cost is of a single whole genome sequencing test for (a) blood cancers and (b) other cancer types.
tabling member constituency	Scunthorpe
tabling member printed	Nic Dakin
uin	269721
answer	answer is ministerial correction date of answer 05/07/2019 answer text <p>The National Genomic Test Directory outlines which genomic tests are commissioned by the National Health Service in England, the technology by which they are available, and the patients who will be eligible to access to a test. The Directory will be updated on an annual basis and NHS England will implement a clear and transparent process, supported by a Clinical and Scientific Expert Panel, to determine which tests are available within the NHS. This will include reviewing any tests that may be retired or replaced by more modern technology, such as whole genome sequencing. As the price of whole genome sequencing falls and the clinical evidence improves, we envisage that it will be extended to more conditions and therefore more patients. More information on the Directory is available at the following link:</p><p> </p><p><a href="https://www.england.nhs.uk/publication/national-genomic-test-directories/" target="_blank">https://www.england.nhs.uk/publication/national-genomic-test-directories/</a></p><p> </p><p>There is considerable variation in the reported costs of genomic analysis. For Genomics England, during the 100,000 Genomes project, these were in order of £2,500 per cancer patient. This included sequencing both the patient’s normal genome and their tumour, as well as the running costs of undertaking both the sequencing and bioinformatics for analysis and interpretation.</p><p>Health Education England established the Genomics Education Programme to support NHS staff to build the knowledge, skills and experience to deliver a whole genome sequencing service. This programme is being embedded into organisations to enable long-term sustainability of the multi-disciplinary clinical workforce.</p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage grouped question UIN 269720 269722 question first answered 05/07/2019 09:26:34 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4056 label Biography information for Nic Dakin